Baricitinib delays the progression of type 1 diabetes
In a world-first, ATIC researchers lead by Professor’s Thomas Kay and Helen Thomas have shown that baricitinib, an immunotherapy treatment commonly used in rheumatoid arthritis, can delay the progression of type 1 diabetes and preserve the body’s ability to make its own insulin.
What does ATIC do?
ATIC is working across six distinct interconnected Domains to ensure maximum impact and fulfil our bold vision.
Clinical trials
Drive the implementation of immunotherapy clinical trials throughout Australia and New Zealand
Community engagement
Work closely with the type 1 diabetes community across the research cycle, from trial development through recruitment to communication of...
Data management
Harmonise data collection and ensure linkage with national and international diabetes networks.
Education and training
Train, equip and update clinicians, scientists and the wider community on the fundamentals of immunotherapy, as well as the latest...
Preclinical and translation
Attract immunotherapy trials to Australasia through innovation: the discovery of improved biomarkers, development of new therapies, and facilitation of biosample...
Regulation and government
Advocate for regulatory approval and government funding of immunotherapy treatments for type 1 diabetes.
T1D RELAY - Rituximab-pvvr and Abatacept Newly Diagnosed Study
ATIC is conducting the TrialNet lead T1D RELAY trial in Melbourne at The Royal Melbourne Hospital. T1D RELAY is available for people ages 8-45 years who have been diagnosed with type 1 diabetes in the last three months.
ATIC Position statement: Use of baricitinib to treat type 1 diabetes
August 2024
The ATIC community engagement panel and steering committee have supported the preparation of a position statement on the use of off-label baricitnib.
Development and deployment of agglutination-PCR testing for islet autoantibodies
August 2024
Seminar 19, Beyond Insulin Seminar Series – A/Prof John Wentworth presents ‘Development and deployment of agglutination-PCR testing for islet autoantibodies’.
Care pathways for people with early-stage type 1 diabetes in Australia
July 2024
A group of ATIC clinician-researchers with support from JDRFA have published the Australian guidelines “Care pathways for people with early-stage type 1 diabetes in Australia”.
Making a National Screening Program for Type 1 Diabetes a Reality in Australia: Progress and Plans
July 2024
Seminar 18, Beyond Insulin Seminar Series – Dr Kirstine Bell presents ‘Making a National Screening Program for Type 1 Diabetes a Reality in Australia: Progress and Plans’
We partner with global leaders in our field
Supported by
Coordinating Centre
